title: Letter to the editor: Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization.
authors.affiliation: National Healthcare Group Eye Institute, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore, Singapore, 308433.
authors.forename: Milton C
authors.initials: MC
authors.lastname: Chew
authors.affiliation: National Healthcare Group Eye Institute, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore, Singapore, 308433. Colintan_eye@yahoo.com.sg.|Fundus Image Reading Center, National Healthcare Group Eye Institute, Singapore, Singapore. Colintan_eye@yahoo.com.sg.
authors.forename: Colin S
authors.identifier: http://orcid.org/0000-0003-3088-5690
authors.initials: CS
authors.lastname: Tan
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D006801:Humans; D058449:Intravitreal Injections; D047728:Myopia, Degenerative / Q000188:drug therapy; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab